By means of this tool, patients are assigned to a low-, intermediate-, or high-risk group based on the criteria of age over 60 years, presence of the driver mutation JAK2-V617F, presence of cardiovascular risk factors, and history of thrombosis [94]. This evidence concerns the gene JAK2 and Venous thrombosis.